v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities:        
Net loss $ (13,040,293) $ (998,271) $ (16,478,995) $ (2,257,890)
Adjustments to reconcile net loss to net cash used in operating activities:        
Amortization of intangible assets     1,149,426  
Amortization of debt discount     688,226  
Goodwill impairment 10,070,124 0 10,070,124 0
Stock-based compensation     1,324,750  
Change in right-of-use assets       17,994
Impairment of right-of-use assets       108,759
Changes in assets and liabilities:        
Trade receivable     (49,604)  
Other current assets     937,246  
Prepaid expenses     (357,144) 1,160
Lease liabilities       (4,925)
Deposits       49,129
Deferred tax liability     (437,677)  
Accounts payable     (860,009) 339,199
Accrued expenses     92,150 163,396
Other current liabilities     83,967  
Other operating assets and liabilities, net     545,969 709,665
Net cash used in operating activities     (3,291,571) (873,513)
Cash flows from financing activities:        
Proceeds from issuance of common stock, pre-funded warrants and warrants, net     3,289,983  
Repayment of revolving loan principal     (700,000)  
Proceeds from promissory notes     999,000 700,000
Proceeds from warrant exercises     555,320  
Net cash provided by financing activities     4,144,303 700,000
Effect of exchange rate changes on cash     (372,795)  
Net increase (decrease) in cash, cash equivalents and restricted cash     479,937 (173,513)
Cash, cash equivalents and restricted cash, beginning balance     899,784 184,992
Cash, cash equivalents and restricted cash, ending balance 1,379,721 11,479 1,379,721 11,479
Reconciliation of cash, cash equivalents and restricted cash:        
Cash and cash equivalents 1,379,721 4,474 1,379,721 4,474
Restricted cash   7,005   7,005
Cash, cash equivalents and restricted cash 1,379,721 11,479 1,379,721 11,479
Non-cash investing and financing activities:        
Accrued dividends on Series B preferred stock $ 163,427 $ 163,428 163,427 $ 163,428
Warrants granted with promissory notes     318,428  
Promissory notes settled for warrant exercises     701,780  
Shareholder receivable related to warrant exercises     163,500  
Subscription receivable related to private placements     4,199,999  
Common stock issued in settlement of accounts payable     227,730  
Common stock issued in settlement of accrued interest on revolving loan     232,315  
Promissory note settled in connection with May 2026 private placement     $ 300,000